Group 1 - The core viewpoint of the article highlights that China National Pharmaceutical Group Technology Co., Ltd. (国药科技股份) reported a significant improvement in its financial performance for the year ending June 30, 2025, with revenue reaching approximately HKD 61.3 million, representing a year-on-year increase of about 48% [1] - The company reported a loss attributable to shareholders of approximately HKD 0.9 million, which is a substantial reduction of about 95% compared to the previous year [1] - The increase in revenue is primarily attributed to the rising demand in the health products market and improved operational efficiency in supply chain services, underscoring the effectiveness of the company's strategic focus on these core business areas [1] Group 2 - The board of directors noted that the significant improvement in the group's financial performance this year is mainly due to several net impacts, including a gross profit increase of approximately HKD 9.2 million or 184% year-on-year due to business improvements [1] - The company has strengthened cost control over administrative and operational expenses [1] - The company recorded capitalized loan income of approximately HKD 3.9 million this year, which contributed to a reduction in financing costs due to the capitalized loans [1]
国药科技股份(08156)公布年度业绩 公司拥有人应占亏损约90万港元 同比大幅减少约95%